Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence

Budczies, 2019, Optimizing panel-based tumor mutational burden (TMB) measurement, Ann. Oncol., 30, 1496, 10.1093/annonc/mdz205 Chan, 2019, Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic, Ann. Oncol., 30, 44, 10.1093/annonc/mdy495 Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat. Med., 24, 1441, 10.1038/s41591-018-0134-3 Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat. Rev. Cancer, 19, 133, 10.1038/s41568-019-0116-x Kazdal, 2019, Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts, J. Thorac. Oncol., 14, 1935, 10.1016/j.jtho.2019.07.006 Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol., 21, 1353, 10.1016/S1470-2045(20)30445-9 Meléndez, 2018, Methods of measurement for tumor mutational burden in tumor tissue, Transl. Lung. Cancer. Res., 7, 661, 10.21037/tlcr.2018.08.02 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet., 51, 202, 10.1038/s41588-018-0312-8 Stenzinger, 2020, Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study, J. Thorac. Oncol., 15, 1177, 10.1016/j.jtho.2020.01.023